

## Frequency and Distinctive Spectrum of *KRAS* Mutations in Never Smokers with Lung Adenocarcinoma

Gregory J. Riely,<sup>1</sup> Mark G. Kris,<sup>1</sup> Daniel Rosenbaum,<sup>1</sup> Jenifer Marks,<sup>1</sup> Allan Li,<sup>2</sup> Dhananjay A. Chitale,<sup>2</sup> Khedoudja Nafa,<sup>2</sup> Elyn R. Riedel,<sup>4</sup> Meier Hsu,<sup>4</sup> William Pao,<sup>1,3</sup> Vincent A. Miller,<sup>1</sup> and Marc Ladanyi<sup>2,3</sup>

**Abstract** **Purpose:** *KRAS* mutations are found in ~25% of lung adenocarcinomas in Western countries and, as a group, have been strongly associated with cigarette smoking. These mutations are predictive of poor prognosis in resected disease as well as resistance to treatment with erlotinib or gefitinib. **Experimental Design:** We determined the frequency and type of *KRAS* codon 12 and 13 mutations and characterized their association with cigarette smoking history in patients with lung adenocarcinomas. **Results:** *KRAS* mutational analysis was done on 482 lung adenocarcinomas, 81 (17%) of which were obtained from patients who had never smoked cigarettes. *KRAS* mutations were found in 15% (12 of 81; 95% confidence intervals, 8-24%) of tumors from never smokers. Similarly, 22% (69 of 316; 95% confidence intervals, 17-27%) of tumors from former smokers, and 25% (21 of 85; 95% confidence intervals, 16-35%) of tumors from current smokers had *KRAS* mutations. The frequency of *KRAS* mutation was not associated with age, gender, or smoking history. The number of pack years of cigarette smoking did not predict an increased likelihood of *KRAS* mutations. Never smokers were significantly more likely than former or current smokers to have a transition mutation (G→A) rather than the transversion mutations known to be smoking-related (G→T or G→C;  $P < 0.0001$ ). **Conclusions:** Based on our data, *KRAS* mutations are not rare among never smokers with lung adenocarcinoma and such patients have a distinct *KRAS* mutation profile. The etiologic and biological heterogeneity of *KRAS* mutant lung adenocarcinomas is worthy of further study.

Since the identification of somatic epidermal growth factor receptor (*EGFR*) mutations, there has been heightened interest in the molecular basis of lung cancer in patients who never smoked cigarettes (1–3). Somatic mutations in *EGFR* have been identified in ~15% of all patients with lung adenocarcinoma, with the proportion increasing to 50% in patients who never smoked cigarettes. There is an inverse relationship between cigarette smoking history and frequency of *EGFR* mutations, with the frequency of *EGFR* mutations decreasing significantly among patients who smoked more than 15 pack years (4). Such refined understanding of the relationship between smoking history and presence of *EGFR* mutations has allowed the design of clinical trials which use smoking history to enrich the number of patients with somatic *EGFR* mutations (5–7).

In contrast to *EGFR* mutations, *KRAS* mutations were initially identified in patients with lung adenocarcinoma who had a history of heavy cigarette smoking and were thought to be uncommon in patients without a history of smoking cigarettes (8). These mutations are found in ~25% of lung adenocarcinomas in western countries but are less common in Asian populations (9, 10). *KRAS* mutations have been associated with poor prognosis in resected non-small cell lung cancer (NSCLC; refs. 11–13), lack of survival benefit from adjuvant chemotherapy (14), and resistance to erlotinib or gefitinib (15). More than 95% of *KRAS* mutations in lung cancer occur in codons 12 and 13. In both *KRAS* and *TP53*, transversions (substituting a pyrimidine for a purine or purine for a pyrimidine) are more common than transitions (substituting purine for purine or pyrimidine for pyrimidine) identifying a molecular signature for the carcinogenic effects of cigarette smoke (16, 17). A detailed analysis of *KRAS* mutations in relation to smoking history has not been done. Using a cohort of patients with lung adenocarcinoma, we sought to determine the frequency and type of *KRAS* mutations in a large series of patients with known smoking histories.

**Authors' Affiliations:** <sup>1</sup>Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, <sup>2</sup>Department of Pathology, <sup>3</sup>Human Oncology Pathogenesis Program, and <sup>4</sup>Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York  
Received 3/10/08; revised 5/20/08; accepted 5/21/08.

**Grant support:** Supported in part by NIH P01 CA129243 (M.G.K., W.P., and M.L.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Note:** V.A. Miller and M. Ladanyi contributed equally to this work.

**Requests for reprints:** Gregory J. Riely, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Phone: 212-639-3042; Fax: 212-794-4357; E-mail: rielyg@mskcc.org.

©2008 American Association for Cancer Research.  
doi:10.1158/1078-0432.CCR-08-0646

### Materials and Methods

Tumor specimens were obtained from an institutional tumor bank of patients who had undergone NSCLC resections between 2002 and 2007, as well as from patients with metastatic NSCLC who had *KRAS* mutation testing done as part of clinical trials or during routine clinical practice. Because *KRAS* mutations are rare in squamous tumors, only

### Translational Relevance

Mutations in the *KRAS* oncogene are found in ~25% of lung adenocarcinomas in Western countries. Studies have linked *KRAS* mutations with poor prognosis in non-small cell lung cancer as well as resistance to treatment with erlotinib or gefitinib. These mutations have been reported to be strongly associated with cigarette smoking. However, previous studies which explored the association of smoking with *KRAS* mutation did not include large numbers of patients who never smoked cigarettes. We report that *KRAS* mutations are found in 15% of lung adenocarcinomas from patients who never smoked cigarettes compared with 22% in patients with a history of smoking cigarettes, a statistically insignificant difference in this study. Furthermore, the frequency of *KRAS* mutation was not associated with age, gender, or smoking history, making it difficult to predict which tumors have *KRAS* mutations by any clinical characteristics. Based on these data, we believe that molecular testing for *KRAS* mutations is necessary to identify this subgroup of patients with a different response to some treatments.

specimens with a histologic diagnosis of lung adenocarcinoma were included. All tumor specimens used for *KRAS* sequencing had >50% tumor. Specimens were microdissected as needed. This retrospective review was done under a waiver of authorization approved by the Memorial Sloan-Kettering Cancer Center Institutional Review Board. Standard direct sequencing was used to identify *KRAS* codon 12 and 13 mutations in tumors (15).

Patient smoking history was obtained by review of a patient-completed smoking questionnaire and the medical record. The prospectively administered questionnaire contained the following questions: Have you smoked more than 100 cigarettes in your life? Are you currently smoking? How many years have you been a regular smoker; and on average, how many cigarettes did you smoke per day? The smoking questionnaire was administered at the time of the first evaluation by a thoracic surgeon or medical oncologist at this institution. Never smokers had smoked <100 cigarettes. Former smokers had previously smoked cigarettes but quit smoking more than 1 year prior to diagnosis of lung cancer. Pack years of smoking was defined as [(average number of cigarettes per day / 20) × years smoking].

### Results

In 482 lung adenocarcinomas, *KRAS* mutations in codons 12 or 13 were found in 21% (102 of 482; 95% confidence

intervals, 18-25%). Patients whose tumors harbored *KRAS* mutations were not significantly different from patients with *KRAS* wild-type tumors with regard to gender, age, or prior smoking history (Table 1). *KRAS* mutations were identified in 15% (12 of 81; 95% confidence intervals, 8-24%) of never smokers, 22% (69 of 316; 95% confidence intervals, 17-27%) of former smokers, and 25% (21 of 85; 95% confidence intervals, 16-35%) of current smokers (Fig. 1). No tumor with a *KRAS* mutation had a mutation in *EGFR*. There were no significant differences in frequency of *KRAS* mutations by category of smoking history (Mantel-Haenszel  $\chi^2$   $P = 0.12$ ). Next, we examined the frequency of *KRAS* mutation by pack years of cigarette smoking (Table 2), and found no trend (Mantel-Haenszel  $\chi^2$   $P = 0.19$ ). To determine whether there was a cutpoint for pack years of cigarette smoking above which *KRAS* mutations were more frequent, a receiver operating characteristic curve was generated. The area under the receiver operating characteristic curve was 0.56 (data not shown) suggesting no value in using pack years of cigarette smoking to predict *KRAS* mutational status.

To determine whether the type of *KRAS* mutation identified in never smokers correlated with the previously described dominance of transversions in smoking-associated cancers, we compared the type of *KRAS* mutation found in never smokers to those found in former or current smokers (Table 3). Never smokers were significantly more likely (Fisher's exact test  $P < 0.0001$ ) to have a transition mutation. The ratio of transition/transversion for never smokers was 11:1 as compared with 17:73 for former or current smokers.

### Discussion

In these patients with lung adenocarcinoma, we find that *KRAS* mutations are not rare in never smokers. This is a striking finding given the widespread perception that cigarette smoking and *KRAS* mutations are invariably linked (reviewed in ref. 16). The association between cigarette smoking and *KRAS* mutations has been inferred from a number of series that included a relatively small numbers of patients who never smoked cigarettes. For example, Nelson et al. examined tumors from 365 patients with NSCLC, of which only 22 were never smokers (18). Among the patients in that series in which *KRAS* mutational analysis was done, there were only 16 never smokers, none of whom had *KRAS* mutations. However, another series which included some never smokers did identify *KRAS* mutation in 14% (3 of 21) of never smokers (19). A difference between our series and previous series is the method

**Table 1.** *KRAS* codon 12 and 13 mutations and clinical characteristics

	All	Mutant <i>KRAS</i>	Wild-type <i>KRAS</i>	P
Total	482	102 (21%)	380 (79%)	
Men	197 (41%)	40 (39%)	157 (41%)	0.73*
Women	285 (59%)	62 (61%)	223 (59%)	
Never smokers	81 (17%)	12 (12%)	69 (18%)	0.14*
Former/current smokers	401 (83%)	90 (88%)	311 (82%)	
Age, median (range)	68 (30-89)	68 (33-85)	67 (30-89)	0.98 †

\*Fisher's exact test.

† Wilcoxon rank sum test.




Fig. 1. Frequency of KRAS mutation by smoking history. Mantel-Haenszel  $\chi^2$  test for trend was used to calculate P value.

of collection of smoking history. We determined smoking history using prospectively collected smoking questionnaires completed by patients with a diagnosis of lung cancer. These patients completed a detailed questionnaire which included the age of onset of smoking, the average number of cigarettes per day, the number of years in which they smoked cigarettes, and the time that the patient quit smoking cigarettes. The characteristics of patients included in this analysis are similar to the patient population seen at our institution with regard to age, gender, and smoking history.

The KRAS mutations observed in these never smokers, in addition to being more frequent than previously reported, are more likely to be transitions, unlike the transversions more common in patients with a history of cigarette smoking. In both KRAS and TP53, transversions (substituting a pyrimidine for a purine, or purine for a pyrimidine) are more common than transitions (substituting purine for purine, or pyrimidine for pyrimidine; refs. 16, 17). The etiology of G→T transversions in tumors from patients with lung cancer is thought to be related to exposure to polycyclic aromatic hydrocarbons found in cigarette smoke (20). In the case of TP53, investigators have recently noted that TP53 G→T

Table 3. KRAS mutation type as a function of smoking history

KRAS		Former/current	Never	Total
Mutation	Nucleotide			
G12A	GGT→GCT	13	0	13
G12C	GGT→TGT	38	0	38
G12V	GGT→GTT	20	1	21
G13C	GGC→TGC	2	0	2
G13D	GGC→GAC	1	0	1
G12D	GGT→GAT	15	10	25
G12S	GGT→AGT	1	1	2
Total		90	12	

transversions were distinctly uncommon in lung adenocarcinomas with EGFR mutations, a mutation more commonly seen in never smokers (21).

Because patients without smoking history represent ~15% of patients with lung cancer, it is critical that any analysis seeking to examine the biology of these tumors examine a relatively large number of patients with NSCLC (22, 23). Relatively little is understood about the biology and epidemiology of lung cancer in never smokers. A number of possible causative factors have been suggested including exposure to environmental tobacco smoke or radon, as well as genetic and hormonal abnormalities (reviewed in refs. 24, 25). The distinct profile of KRAS mutations observed here in never smokers further suggests that such cancers are only rarely caused by environmental tobacco exposure. Whether this etiologic heterogeneity within KRAS mutant lung adenocarcinomas is associated with differences in cooperating genetic lesions and overall biological behavior warrants further investigation. Finally, because tumors from never smokers may have KRAS mutations, and such mutations have been associated with resistance to erlotinib and gefitinib (15), molecular analysis of NSCLC specimens for KRAS mutations may improve a clinician's ability to predict response and resistance to therapy with erlotinib or gefitinib.

#### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Table 2. Frequency of KRAS mutation by smoking history in pack years

	Mutant	Wild-type	Total	Frequency (%)	95% Confidence intervals (%)
Never smokers	12	69	81	15	8-23
<5 py	3	25	28	11	2-28
6-10 py	3	25	28	11	2-28
11-15 py	6	13	19	32	13-57
16-25 py	10	45	55	18	9-31
26-50 py	40	106	146	27	20-35
51-75 py	16	51	67	24	14-36
>75 py	12	46	58	21	11-33
Total	102	380	482	21	

Abbreviation: py, pack years.

## References

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129–39.
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib and erlotinib. *Science* 2004;304:1497–500.
3. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A* 2004;101:13306–11.
4. Pham D, Kris MG, Riely GJ, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. *J Clin Oncol* 2006;24:1700–4.
5. Cappuzzo F, Ligorio C, Janne PA, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence *in situ* hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. *J Clin Oncol* 2007;25:2248–55.
6. Kris MG, Pao W, Zakowski M, et al. Prospective trial with preoperative gefitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy. 2006 ASCO Annual Meeting; 2006; Atlanta (GA): Am Soc Clin Oncol; 2006. p. 369s.
7. Sequist LV, Martins RG, Spigel D, et al. Fine-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. *J Clin Oncol* 2008;26:2442–9.
8. Rodenhuis S, van de Wetering ML, Mooi WJ, et al. Mutational activation of the K-ras oncogene: a possible pathogenetic factor in adenocarcinoma of the lung. *N Engl J Med* 1987;317:929–35.
9. Buttitta F, Barassi F, Fresu G, et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. *Int J Cancer* 2006;119:2586–91.
10. Suzuki M, Shigematsu H, Iizasa T, et al. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of non-small cell lung cancer. *Cancer* 2006;106:2200–7.
11. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. *J Clin Oncol* 1999;17:668–75.
12. Slebos R, Kibbelaar R, Dalesio O. K-RAS oncogene activation as a prognostic marker in adenocarcinoma of the lung. *N Engl J Med* 1990;323:561–5.
13. Rosell R, Molina F, Moreno I, et al. Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer. *Lung Cancer* 1995; 12Suppl 1:S59–70.
14. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. *N Engl J Med* 2005;352:2589–97.
15. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. *PLoS Med* 2005;2:e17.
16. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. *Cancer* 2001;92:1525–30.
17. Hainaut P, Pfeifer GP. Patterns of p53 G to T transversions in lung cancer reflect the primary mutagenic signature of DNA-damage by tobacco smoke. *Carcinogenesis* 2001;22:367–74.
18. Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC, Kelsey KT. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. *J Natl Cancer Inst* 1999;91:2032–8.
19. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. *J Clin Oncol* 2007;25:5240–7.
20. Hecht SS. Tobacco smoke carcinogens and lung cancer. *J Natl Cancer Inst* 1999;91:1194–210.
21. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. *Cancer Res* 2004;64:8919–23.
22. Parkin DM, Pisani P, Lopez AD, Masuyer E. At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. *Int J Cancer* 1994;59:494–504.
23. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005;55:74–108.
24. Subramanian J, Govindan R. Lung cancer in never smokers: a review. *J Clin Oncol* 2007;25:561–70.
25. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers—a different disease. *Nat Rev Cancer* 2007;7:778–90.

# Clinical Cancer Research

## Frequency and Distinctive Spectrum of *KRAS* Mutations in Never Smokers with Lung Adenocarcinoma

Gregory J. Riely, Mark G. Kris, Daniel Rosenbaum, et al.

*Clin Cancer Res* 2008;14:5731-5734.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/14/18/5731>

**Cited articles** This article cites 24 articles, 9 of which you can access for free at:  
<http://clincancerres.aacrjournals.org/content/14/18/5731.full#ref-list-1>

**Citing articles** This article has been cited by 39 HighWire-hosted articles. Access the articles at:  
<http://clincancerres.aacrjournals.org/content/14/18/5731.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://clincancerres.aacrjournals.org/content/14/18/5731>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.